Skip to main content

GI/Liver

#EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed: - 1 in 10 people had AID in the last 20yrs - socioeconomic, seasonal & regional disparities cd influence pathogenesis - CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC
Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong. Surely this needs more investment?? CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/8BMTmJqhPq https://t.co/BOMsk38KB2
U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults based on induction studies, U-EXCEED, U-EXCEL,& U-ENDURE maintenance study. This is 7th FDA approval for RINVOQ https://t.co/FypYaTMJxU https://t.co/yilppBv6Ka

Juvenile and Adult-onset Scleroderma Differ

May 15, 2023

A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.  

Read Article
REMIT-UC: Tofacitinib study 334 w/ Ulcerative Colitis:Clinical remission in 35%, Endoscopic remission in ~24%; & low risk (per/100PY) of serious infections (2.1), H zoster (0.5), & VTE (1.1). Loss of response in 45%, but recaptured 55% w/ dose escalation https://t.co/KgSrKBbv40 https://t.co/M74l4tOA3U

One in Ten is Bad! (5.12.2023)

May 12, 2023

This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!

Read Article
REMIT-UC: Tofacitinib study 334 w/ Ulcerative Colitis:Clinical remission in 35%, Endoscopic remission in ~24%; & low risk (per/100PY) of serious infections (2.1), H zoster (0.5), & VTE (1.1). Loss of response in 45%, but recaptured 55% w/ dose escalation https://t.co/OgQYcq9pQk https://t.co/1KtLDvkQGT

Want to Go Far, Go Together (4.21.2023)

Apr 21, 2023

This week on the podcast Dr. Jack Cush reviews the news, regulatory announcements and novel journal reports including a profile on pseudogout, the safety of immune checkpoint inhibitors in RA patients and the diagnostic importance of neutrophils.




  1. CIRCS study: Comparison of

Read Article

The Match Game (4.14.2023)

Apr 14, 2023

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.




  1. 2023 NRMP Match: 365 applicants for Rheum; 97.8% (265 of 271

Read Article
FDA FAERS study of IL-17 inhib & colitis: 388 pts w/ suspected IL-17i assoc. IBD. Median age - 42 yrs; Initial Sxs= diarrhea 91%, Abd pain 58%, bloody diarrhea 51%), & fever 36%, ^WBC 87%; Time to onset=2.9 mos. Time to remission after IL-17i D/C =4 wks https://t.co/adrtUhFj9C https://t.co/61GC5hvzYV
Commercial claims analysis shows a significant association between acne and incident #IBD (OR 1.42; 1.23-1.65), but not with the drugs used to treat acne (tetracycline-class Abx or isotretinoin) https://t.co/VSHMRw4z7c https://t.co/S2o6Xw3Mfd

LAVLI - A New Autoinflammatory Disorder

Mar 28, 2023

NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes systemic

Read Article
Dr. John Reveille on genetic sharing between AS, PsO, and IBD - multiple overlapping genetic signals @RheumNow #RNL2023 https://t.co/p3gvfTO732
Year in Review by Dr. Cush and Dr. Kavanaugh Combo biologic therapy? Phase II study from GI colleagues for UC Guselkumab + golimumab - no additional safety concerns - improved clinical response - extrapolate to rheumatology use? #RNL2023 @RheumNow https://t.co/DirAovm1AX
Renal Involvement is Pivotal in ANCA-Associated Vasculitis Researchers have identified four different trajectories of kidney function over time in AAV patients, with implications for personalized treatment, as well as future research. https://t.co/O8EaW2MaBx https://t.co/VApYiH66yn

NSAIDs in Pregnancy (3.3.2023)

Mar 03, 2023

Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow.  This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.




  1. Study of 87 pts with isolated Nail Psoriasis noted that 11% went on to have

Read Article

VEGA - The Efficacy of Combination Biologics in Ulcerative Colitis

Mar 02, 2023

A novel trial has shown that combination biologic therapy (guselkumab plus golimumab) to be more effective in ulcerative colitis than either biologic alone.

Read Article

Periodontal Mucosal Breaks Trigger RA Disease Activity

Feb 23, 2023

Periodontal disease (PD) is more common in rheumatoid arthritis (RA), especially those with anti-citrullinated protein antibodies (ACPAs).  RA activity has been linked to the severity of PD and mucosal inflammation.



Researchers from Standfod have suggested a prominent role for PD in

Read Article
211 Adult Crohn's pts w/ steroid-free remission >6mo on Combo infliximab & immunosuppressant either cont combo or W/D IFX or Immsup. 2-yr relapse rates: 14% Combo vs, 36% IFX vs 10% Immunosup. WD of IFX had 3.45-4.76 fold incr rsk of flare https://t.co/6EbM3Vx0Ei https://t.co/5ZOE2oxCl0
Subanalysis of Scleroderma Lung Study II (MMP vs CTX in SSc-ILD) showed pt reported GI reflux (~moderate) was independently associated with the change ILD and fibrosis over two years (but not so for esophageal dilation) https://t.co/5Gz2vfOock https://t.co/N2FsvNe24M

Rheumatic Disease - IBD Overlap

MedPage Today
Jan 26, 2023

Nearly one in 10 patients with inflammatory bowel disease (IBD) also have rheumatologic disorders, meaning that specialists have to talk to each other to develop a treatment plan that works for both conditions, a researcher suggested.



Of 228 IBD patients treated in the clinic, 9.2%

Read Article
Danish registries stud of > 6 million persons finds 52898 new #IBD pts (over 18 yrs). Antibiotic exposure was assoc w/ increased risk of IBD, esp > 40 yrs. (40–60 yrs IRR 1.48; ≥60 yrs IRR 1.47) https://t.co/qU1OxXr7Gj https://t.co/YMh6L514By

PsA Til Death Do Us Part (1.20.2023)

Jan 20, 2023

Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.

Read Article
Danish registries stud of > 6 million persons finds 52898 new #IBD pts (over 18 yrs). Antibiotic exposure was assoc w/ increased risk of IBD, esp > 40 yrs. (40–60 yrs IRR 1.48; ≥60 yrs IRR 1.47) https://t.co/3P5WSjZm8M https://t.co/xHNFMWQ8dC
×